ACT	Adoptive Cell Therapy
ADC	Antibody–Drug Conjugate
AEs	Adverse Events
ALK	Anaplastic Lymphoma Kinase
ALT	Alanine Aminotransferase
AST	Aspartate Aminotransferase
bsAbs	Bispecific Antibodies
CNS	Central Nervous System
CR	Complete Response
CTLA-4	Cytotoxic T-Lymphocyte-Associated Protein 4
DOR	Duration of Response
EGFR	Epidermal Growth Factor Receptor
ex20ins	Exon 20 insertion
FDA	Food and Drug Administration
HER2	Human Epidermal Growth Factor Receptor 2
HER3	Human Epidermal Growth Factor Receptor 3
HR	Hazard Ratio
ICIs	Immune Checkpoint Inhibitors
ILD	Interstitial Lung Disease
KRAS	Kirsten Rat Sarcoma Viral Oncogene Homologue
LAG–3	Lymphocyte-Activation Gene 3
LCINS	Lung Cancer in Never-Smokers
MEK	Mitogen-Activated Protein Kinase
MET	Mesenchymal-Epithelial Transition factor
METex14	Mesenchymal-Epithelial Transition Factor Exon 14 Skipping Mutation
M2	Macrophages
NSCLC	Non–Small Cell Lung Cancer
ORR	Objective Response Rates
OS	Overall Survival
PD-1	Programmed Cell Death Protein 1
PD-L1	Programmed Death-Ligand 1
PFS	Progression-Free Survival
QT	QT Interval
RET	Rearranged during Transfection
ROS1	c-Ros Oncogene 1
T cell	T Lymphocytes
TIGIT	T-cell Immunoreceptor with Immunoglobulin and Immunoreceptor Tyrosine-Based Inhibition Motif Domains
TILs	Tumor-Infiltrating Lymphocytes
TKIs	Tyrosine Kinase Inhibitors
TMB	Tumor Mutational Burden
TME	Tumor Microenvironment
TRK	Tyrosine Receptor Kinase
vs.	Versus